The application of Heberprot-P will begin at The First Hospital in Ulaanbaatar.

Ulaanbaatar, Mongolia. February 23, 2019. With the signing of a Memorandum of Understanding between The First Hospital of Ulaanbaatar, IMPEX Concern and the Center for Genetic Engineering and Biotechnology (CIGB) will begin  the application of the new Cuban treatment for diabetic foot ulcers to the patients in this public hospital of the capital of Mongolia. The document signed between these three entities will allow in the coming days to begin the training of the Mongolian medical specialists who will apply the Cuban biotechnological medicine to diabetic patients who suffer from the complications of ulcers associated with this disease.

The Director General of Hospital No. 1 Dr. Chuluunbaatar Donkhim expressed during the signing of the document that: "With the possibilities offered by this treatment and the Cuban experience in the treatment of these complications, they will be able to save many diabetic Mongolian patients that today they have no other way out than the amputation once these ulcers appear. " The registration of Heberprot-P in Mongolia, on May 1, 2018, by the pharmaceutical company IMPEX Concern, commercial partner of CIGB, opened new possibilities in the treatment and cure of these complications to Mongolian patients.

Representing CIGB, Cuban Ambassador Raúl Delgado Concepción, expressed his gratitude to this Mongolian public hospital for his interest in preparing his medical professionals for the application of this product known worldwide for its effectiveness. Since 2018 the CIGB has been working with the Mongolian Diabetes Center in the training of medical professionals to improve the quality of life of this sector of the population in Mongolia that today suffers from diabetes and its complications. (EmbaCuba Mongolia)

Relaciones Bilaterales
RSS Minrex